Genmab — Maj 2025

[E_L]

New acasunlimab melanoma trail !!: Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07) https://clinicaltrials.gov/study/NCT06984328

[gentogen]

Ja, det fortjener et par udråbstegn. Selv om vi mere håber og venter på fase 3, så det vel alligevel ses som interessant og positivt med nyt område
.

[ProinvestorNEWS]

Deutsche Bank skærer 7,9 pct. af Genmabs kursmål men gentager "køb" https://proinvestor.com/investornyt/1321059/deutsche-bank-skaerer-79-pct-af-genmabs-kursmal-men-gentager-kob

[E_L]

ASCO 25
Rinatabart sesutecan (Rina-S) for patients with advanced endometrial cancer: First disclosure from dose expansion cohort B2 of the GTC1184-01 study. https://meetings.asco.org/abstracts-presentations/246292

[E_L]

ASCO 25 A phase 3, open-label, randomized study of rinatabart sesutecan (Rina-S) vs investigator’s choice (IC) of chemotherapy in patients with platinum-resistant ovarian cancer (PROC) https://meetings.asco.org/abstracts-presentations/252407

[E_L]

ASCO 25 Novel analysis of 3-y results from the pivotal EPCORE NHL-1 study: Outcomes in patients (pts) with relapsed/refractory large B-cell lymphoma (R/R LBCL) and complete response (CR) at 2 y with epcoritamab (epcor) monotherapy. https://meetings.asco.org/abstracts-presentations/246029

[E_L]

ASCO 25 First data from phase 1b/2 EPCORE NHL-4: Epcoritamab (Epcor) in Chinese patients (Pts) with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL). https://meetings.asco.org/abstracts-presentations/246176

[Solsen]

Spændende resultater i endometrial cancer. Her ser 100 mg at være tilstrækkelig og med et dødsfald i 120 mg gruppen. Ikke optimalt men svære pts at behandle.

[Solsen]

Rina-S har ikke Elaheres achilleshæl bivirkninger “ No signals of ocular toxicity, neuropathy, or interstitial lung disease were observed”

[JKY_VH]

Fra MW "Genmab vil over flere omgange præsentere data fra sin pipeline i forbindelse med årsmødet his American Society of Clinical Oncology (ASCO) i starten af juni.

Præsentationerne inkluderer den første offentliggørelse af resultater fra et fase 1/2-studie med Rina-S til behandling af kræft i livmoderen."

[E_L]

For Ovarian Cancer there was a big difference between the 100 and 120mg dose, 120mg much better. Safety for endometrial seems slightly better?

[E_L]

Johnson & Johnson showcases latest advancements in cancer innovation with more than 70 clinical and real-world studies at ASCO and EHA https://www.jnj.com/media-center/press-releases/johnson-johnson-showcases-latest-advancements-in-cancer-innovation-with-more-than-70-clinical-and-real-world-studies-at-asco-and-eha

[E_L]

Redburn lowers target price for Genmab to DKK 2,700 (2,750), reiterates buy recommendation (part of the Rothschild group)

[E_L]

How Insourcing Transformed Antibody Manufacturing Success https://bioprocessupdates.com/upstream/how-insourcing-transformed-antibody-manufacturing-success/

[E_L]

perplexity analysis Rina-S...not sure if this link will work for others...
: https://www.perplexity.ai/search/results-how-does-this-new-data-YPc0_alLR5iBhcEc4MOBsw

[bikube]

Virker fint her.

[Solsen]

Dejlig sætning “If these results are confirmed in larger, longer-term studies, Rina-S could become a best-in-class option for this difficult-to-treat population”

[Solsen]

Thanks EL

[gentogen]

Thanks. Top nice...

[Solsen]

Stort marked for behandling af endometrial cancer https://www.gminsights.com/industry-analysis/endometrial-cancer-treatment-market